<DOC>
	<DOC>NCT00333294</DOC>
	<brief_summary>The objective of this study is to determine wether the ZD1839 associated with a radiotherapy, before the beginning of chemotherapy is effective in the treatment of your disease and to evaluate the tolerance of these treatments.</brief_summary>
	<brief_title>Phase II Iressa + Irradiation Followed by Chemo in NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Signed informed consent. 18 to 75 years inclusive. At least one measurable lesions histologically confirmed inoperable stage III NSCLC. WHO performance status of 0 to 2 inclusive. Adequate pulmonary function, pulmonary dose volume histogram less than or equal to 40 %. Life expectancy of at least 6 months. Using secure contraceptives precautions. Any previous anti cancer therapy for NSCLC. Known severe hypersensitivity to these products Any evidence of clinically active interstitial lung disease Other coexisting malignancies, symptomatic metastases. Abnormal blood test Weight loss of over 15% in the 3 months before the start of the study. Treatment with a nonapproved or investigational drug within 30 days before Day 1 of study treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>